CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

Omada Health shares climbed after the company made its debut on Nasdaq. The virtual healthcare company started trading shares at $19 on Friday morning, and they jumped 35% to $25.58 by midday. It ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Novo Nordisk's flagship diabetes and weight-loss drugs, Ozempic and Wegovy, have come under heightened scrutiny after the ...

Patients who use GLP1 drugs to help control their type 2 diabetes are at an upward risk of developing age-related macular ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...